We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Fisher & Paykel Healthcare Corp Ltd is a designer, manufacturer and marketer of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The Company operates in four segments: New Zealand. Includes all activities controlled by entities or employees based in New Zealand, principally research and development, manufacturing, marketing, sales and distribution and administration. The research and development activity relates to New Zealand. The manufacturing activity principally relates to New Zealand, however the Mexico manufacturing activity is also included in this segment as the Mexico facility is managed by New Zealand-based employees. The sales and distribution activity principally relates to New Zealand, Latin America, Africa, the Middle East and other countries in Asia. Also included are sales made to countries within Europe and Asia-Pacific where the management of the sale is from New Zealand; North America. Includes all activities controlled by entities or employees based in the United States of America and Canada, principally sales, distribution and administration activities; Europe. Includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden and Turkey, principally sales, distribution and administration activities. These sales and distribution hubs also distribute product into neighboring European countries; and Asia-Pacific. Includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan and Hong Kong, principally sales, distribution and administration activities.
- Recent FSPKF Stock Price: $16.36
- Yearly Gain for FSPKF stock: -16.44%
- Market Cap for FSPKF stock: $9.87B
- P/E Ratio for FSPKF stock: 58.584
Will FSPKF's stock price go up? Is there an accurate FSPKF stock forecast available?
TipRanks.com reports that Fisher & Paykel Healthcare Corporation Limited currently has 11 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $16.15. The target pricing ranges from a high FSPKF forecast of $20.08 down to a low forecast of $13.97. Fisher & Paykel Healthcare Corporation Limited (FSPKF)’s last closing stock price was $16.36 which would put the average price target at -1.28% upside.
In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on FSPKF stock.
Other analysts covering FSPKF include:
- Gretel Janu of Credit Suisse issued a Hold rating with the price target of $ 16.07 on 21 hours ago
- Craig Wong-Pan of RBC Capital issued a Sell rating with the price target of $ 13.97 on 21 hours ago
- Andrew Paine of CLSA issued a Sell rating with the price target of $ 16.9 on 21 hours ago
- David Low of J.P. Morgan issued a Hold rating with the price target of $ 16.55 on 21 hours ago
If you are wondering if FSPKF is a good stock to buy, here are 3rd party ratings for FSPKF stock:
- TipRanks.com: Hold
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Fisher & Paykel Healthcare Corporation Limited? (Current ratings compiled by TipRanks.com)
- News Sentiment for FSPKF stock: Neutral
- Blogger Consensus for FSPKF stock: Bullish
- Media Buzz for FSPKF stock: Very Low
- Insider Signal for FSPKF stock: n/a
- Investor Sentiment for FSPKF stock: n/a
- Hedge Fund signal for FSPKF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on FSPKF stock including scouring the social networks like FSPKF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for FSPKF stock chart >>
Summary: Roche Holding AG Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. It has more than 60 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. Diagnostics division includes five business areas: Applied Science, Molecular Diagnostics, Professional Diagnostics, Tissue Diagnosis and Diabetes Care.
- Recent RHHVF Stock Price: $318.764
- Yearly Gain for RHHVF stock: -14.74%
- Market Cap for RHHVF stock: $262.78B
- P/E Ratio for RHHVF stock: 16.757
Will RHHVF's stock price go up? Is there an accurate RHHVF stock forecast available?
TipRanks.com reports that Roche Holding AG currently has 12 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $375.91. The target pricing ranges from a high RHHVF forecast of $435.63 down to a low forecast of $288.61. Roche Holding AG (RHHVF)’s last closing stock price was $318.764 which would put the average price target at 17.93% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on RHHVF stock.
Other analysts covering RHHVF include:
- Andrew Baum of Citigroup issued a Buy rating with the price target of $ 381.18 on 3 days ago
- Michael Leuchten of UBS issued a Hold rating with the price target of $ 343.06 on 3 days ago
- Richard Vosser of J.P. Morgan issued a Sell rating with the price target of $ 299.5 on 4 days ago
- Emmanuel Papadakis of Deutsche Bank issued a Sell rating with the price target of $ 288.61 on 5 days ago
If you are wondering if RHHVF is a good stock to buy, here are 3rd party ratings for RHHVF stock:
- TipRanks.com: Hold
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Roche Holding AG? (Current ratings compiled by TipRanks.com)
- News Sentiment for RHHVF stock: Neutral
- Blogger Consensus for RHHVF stock: Bullish
- Media Buzz for RHHVF stock: Medium
- Insider Signal for RHHVF stock: n/a
- Investor Sentiment for RHHVF stock: Very Positive
- Hedge Fund signal for RHHVF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on RHHVF stock including scouring the social networks like RHHVF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RHHVF stock chart >>
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
- Recent ICPT Stock Price: $15.91
- Yearly Gain for ICPT stock: 3.27%
- Market Cap for ICPT stock: $667.64M
- P/E Ratio for ICPT stock: 2.809
Will ICPT's stock price go up? Is there an accurate ICPT stock forecast available?
TipRanks.com reports that Intercept Pharma currently has 9 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $22.13. The target pricing ranges from a high ICPT forecast of $35.00 down to a low forecast of $14.00. Intercept Pharma (ICPT)’s last closing stock price was $15.91 which would put the average price target at 39.09% upside.
In addition,Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on ICPT stock.
Other analysts covering ICPT include:
- Joseph Stringer of Needham issued a Buy rating with the price target of $ 22 on 4 days ago
- Steven Seedhouse of Raymond James issued a Buy rating with the price target of $ 26 on 4 days ago
- Brian Skorney of Robert W. Baird issued a Buy rating with the price target of $ 35 on 4 days ago
If you are wondering if ICPT is a good stock to buy, here are 3rd party ratings for ICPT stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Buy, Top 29% (74 out of 251)
What is the sentiment on the street regarding Intercept Pharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for ICPT stock: Very Bullish
- Blogger Consensus for ICPT stock: Bearish
- Media Buzz for ICPT stock: High
- Insider Signal for ICPT stock: n/a
- Investor Sentiment for ICPT stock: Negative
- Hedge Fund signal for ICPT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ICPT stock including scouring the social networks like ICPT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ICPT stock chart >>
Summary: Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
- Recent IOVA Stock Price: $7
- Yearly Gain for IOVA stock: -57.43%
- Market Cap for IOVA stock: $989.66M
- P/E Ratio for IOVA stock: -2.529
Will IOVA's stock price go up? Is there an accurate IOVA stock forecast available?
TipRanks.com reports that Iovance Biotherapeutics currently has 10 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $22.44. The target pricing ranges from a high IOVA forecast of $38.00 down to a low forecast of $6.00. Iovance Biotherapeutics (IOVA)’s last closing stock price was $7 which would put the average price target at 220.57% upside.
In addition, TradingView issued a Buy rating for IOVA stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IOVA stock.
Other analysts covering IOVA include:
- Mara Goldstein of Mizuho Securities issued a Buy rating with the price target of $ 30 on 21 hours ago
- Asthika Goonewardene of Truist Financial issued a Buy rating with the price target of $ 17 on 21 hours ago
- Joseph Pantginis of H.C. Wainwright issued a Buy rating with the price target of $ 38 on 21 hours ago
- Reni Benjamin of JMP Securities issued a Buy rating with the price target of $ 21 on 6 days ago
If you are wondering if IOVA is a good stock to buy, here are 3rd party ratings for IOVA stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Top 29% (74 out of 251)
What is the sentiment on the street regarding Iovance Biotherapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for IOVA stock: Very Bullish
- Blogger Consensus for IOVA stock: Bullish
- Media Buzz for IOVA stock: Very High
- Insider Signal for IOVA stock: Positive
- Investor Sentiment for IOVA stock: Very Negative
- Hedge Fund signal for IOVA stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on IOVA stock including scouring the social networks like IOVA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IOVA stock chart >>
Summary: Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.
- Recent RAIN Stock Price: $9.85
- Yearly Gain for RAIN stock: -2.27%
- Market Cap for RAIN stock: $333.49M
- P/E Ratio for RAIN stock: -3.543
Will RAIN's stock price go up? Is there an accurate RAIN stock forecast available?
TipRanks.com reports that Rain Therapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $17.07. The target pricing ranges from a high RAIN forecast of $29.00 down to a low forecast of $9.49. Rain Therapeutics (RAIN)’s last closing stock price was $9.85 which would put the average price target at 73.30% upside.
In addition, TradingView issued a Buy rating for RAIN stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RAIN stock.
Other analysts covering RAIN include:
- Graig Suvannavejh of Mizuho Securities issued a Buy rating with the price target of $ 18 on 21 hours ago
- Soumit Roy of JonesTrading issued a Buy rating with the price target of $ 20 on 21 hours ago
- Joseph Catanzaro of Piper Sandler issued a Buy rating with the price target of $ 15 on 3 days ago
- Anthony Butler of EF Hutton issued a Buy rating with the price target of $ 16 on 2 weeks ago
If you are wondering if RAIN is a good stock to buy, here are 3rd party ratings for RAIN stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 29% (74 out of 251)
What is the sentiment on the street regarding Rain Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for RAIN stock: Very Bullish
- Blogger Consensus for RAIN stock: Bullish
- Media Buzz for RAIN stock: Low
- Insider Signal for RAIN stock: Positive
- Investor Sentiment for RAIN stock: Very Positive
- Hedge Fund signal for RAIN stock: Neutral
The stock market is extremely volatile, and you need to do your own research on RAIN stock including scouring the social networks like RAIN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RAIN stock chart >>
Summary: Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO, Calif.
- Recent PLRX Stock Price: $30.28
- Yearly Gain for PLRX stock: 97.63%
- Market Cap for PLRX stock: $1.10B
- P/E Ratio for PLRX stock: -7.682
Will PLRX's stock price go up? Is there an accurate PLRX stock forecast available?
TipRanks.com reports that Pliant Therapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $48.43. The target pricing ranges from a high PLRX forecast of $60.00 down to a low forecast of $33.00. Pliant Therapeutics (PLRX)’s last closing stock price was $30.28 which would put the average price target at 55.22% upside.
In addition, TradingView issued a Strong Buy rating for PLRX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on PLRX stock.
Other analysts covering PLRX include:
- Eric Joseph of J.P. Morgan issued a Buy rating with the price target of $ 51 on 21 hours ago
- Pete Stavropoulos of Cantor Fitzgerald issued a Buy rating with the price target of $ 52 on 21 hours ago
- Alex Thompson CFA of Stifel Nicolaus issued a Buy rating with the price target of $ 45 on 21 hours ago
- Ed Arce of H.C. Wainwright issued a Buy rating with the price target of $ 53 on 2 months ago
If you are wondering if PLRX is a good stock to buy, here are 3rd party ratings for PLRX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 29% (74 out of 251)
What is the sentiment on the street regarding Pliant Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for PLRX stock: Very Bullish
- Blogger Consensus for PLRX stock: Bullish
- Media Buzz for PLRX stock: High
- Insider Signal for PLRX stock: Negative
- Investor Sentiment for PLRX stock: Very Negative
- Hedge Fund signal for PLRX stock: Positive
The stock market is extremely volatile, and you need to do your own research on PLRX stock including scouring the social networks like PLRX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PLRX stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================